Literature DB >> 33541386

Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma.

Huijuan Ge1,2, Yaoxin Xiao2,3, Guangqi Qin1,2, Yanzi Gu1,2, Xu Cai1,2, Wenhua Jiang1,2, Xiaoyu Tu1,2, Wentao Yang1,2, Rui Bi4,5.   

Abstract

BACKGROUND: Ovarian clear cell carcinoma (OCCC) is the second subtype of ovarian epithelial carcinoma reported to be closely related to Lynch syndrome (LS). ARID1A mutation is an important pathogenetic mechanism in OCCC that leads to loss of ARID1A expression in approximately half of OCCCs. However, the correlation of MMR status and ARID1A deficiency is unclear. The current study aimed to identify the clinical and histopathological characteristics of OCCC associated with dMMR and to further explore the association between dMMR and ARID1A deficiency.
METHODS: A cohort of 176 primary OCCC patients was enrolled and review included histological characteristics (nuclear atypia, necrosis, mitosis, stromal hyalinization, and background precursors) and host inflammatory response (tumor-infiltrating lymphocytes, peritumoral lymphocytes, intratumoral stromal inflammation and plasma cell infiltration). Immunohistochemical staining of MLH1, PMS2, MSH2, MSH6 and ARID1A was performed using tissue microarrays.
RESULTS: dMMR was detected in 10/176 tumors (6 %), followed by MSH2/MSH6 (6/176), MLH1/PMS2 (3/176), and MSH6 (1/176). The average age of patients with dMMR was younger than that of patients with intact MMR (46 y vs. 53 y). Tumors with diffuse intratumoral stromal inflammation remained significantly associated after multivariate analysis. ARID1A expression was absent in 8 patients with dMMR (8/10), which is a significantly higher frequency than that observed in patients with intact MMR (80 % vs. 43.2 %).
CONCLUSIONS: Our study indicates that diffuse intratumoral stromal inflammation of OCCCs is associated with dMMR, with loss of MSH2/MSH6 expression being most frequent. dMMR is strongly associated with the loss of ARID1A expression in OCCC.

Entities:  

Keywords:  ARID1A; Deficient MMR (dMMR); Diffuse intratumoral stromal inflammation; MSH2/MSH6; Ovarian clear cell carcinoma

Year:  2021        PMID: 33541386     DOI: 10.1186/s13000-021-01071-w

Source DB:  PubMed          Journal:  Diagn Pathol        ISSN: 1746-1596            Impact factor:   2.644


  1 in total

1.  Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.

Authors:  Wenbin Xiao; Amad Awadallah; Wei Xin
Journal:  Int J Clin Exp Pathol       Date:  2012-09-05
  1 in total
  5 in total

1.  Mutational signatures are markers of drug sensitivity of cancer cells.

Authors:  Jurica Levatić; Marina Salvadores; Francisco Fuster-Tormo; Fran Supek
Journal:  Nat Commun       Date:  2022-05-25       Impact factor: 17.694

2.  Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report.

Authors:  Maia L Valls; Adam M Kase; Rina Patel; Benjamin Wang; Rohit Aggarwal; Gerardo Colon-Otero
Journal:  Gynecol Oncol Rep       Date:  2022-05-25

Review 3.  Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers.

Authors:  Yun-Hsin Tang; Chiao-Yun Lin; Chyong-Huey Lai
Journal:  Genes (Basel)       Date:  2021-10-09       Impact factor: 4.096

4.  ARID1A knockdown enhances carcinogenesis features and aggressiveness of Caco-2 colon cancer cells: An in vitro cellular mechanism study.

Authors:  Paleerath Peerapen; Kanyarat Sueksakit; Wanida Boonmark; Sunisa Yoodee; Visith Thongboonkerd
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

5.  Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma.

Authors:  Mayumi Kobayashi Kato; Yuka Asami; Daisuke Takayanagi; Maiko Matsuda; Yoko Shimada; Kengo Hiranuma; Ikumi Kuno; Masaaki Komatsu; Ryuji Hamamoto; Koji Matsumoto; Mitsuya Ishikawa; Takashi Kohno; Tomoyasu Kato; Kouya Shiraishi; Hiroshi Yoshida
Journal:  Cancer Sci       Date:  2022-03-24       Impact factor: 6.518

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.